Partnership Between Solo-Dex and Polymedicure for Introduction of Opioid-Free Acute Pain Management Solutions in India and Key Asian Markets
In a significant move towards enhancing patient care and reducing opioid dependency, Solo-Dex, Inc., a U.S.-based medical device company specializing in opioid-free acute pain management, has formed a strategic partnership with Polymedicure Ltd., one of India's most trusted names in medical devices with a global presence in over 100 countries.
The partnership aims to globally distribute and manufacture Solo-Dex's patented regional anesthesia solutions, with a focus on major Asian markets, including India. The partnership is expected to commence commercial availability of the system in the fourth quarter of 2025.
Steven Eror, CEO of Solo-Dex, expressed his pride in collaborating with Polymed to address the worldwide need for safer, opioid-free surgical recovery. He stated that the partnership will deliver a transformative technology that goes beyond suppressing pain, blocking acute pain completely.
The Solo-Dex Fascile Continuous Peripheral Nerve Block system, already approved for clinical use in the United States and Europe, installs in under two minutes and provides continuous, localized pain relief without the use of opioids. Unlike conventional methods, this system minimizes systemic drug exposure, eliminates the need for oral opioids, and improves patient safety, reduces recovery time, and decreases demand on hospital resources.
The technology is designed to integrate with ERAS (Enhanced Recovery After Surgery) protocols, helping hospitals manage post-operative pain more efficiently. As India's healthcare system embraces day surgery and outpatient models, this solution enhances patient throughput and satisfaction without compromising clinical outcomes.
Polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-quality healthcare solutions at scale. Manufacturing of Solo-Dex's Fascile Continuous Peripheral Nerve Block system will take place in Polymed's ISO 13485-certified, FDA-auditable facilities. Polymed will manufacture the system according to Solo-Dex's quality standards, while Solo-Dex will oversee global regulatory compliance and branding for the system.
The partnership aligns with Polymed's commitment to making world-class healthcare more accessible. As part of the market rollout, the partnership is actively engaging with leading hospital systems in India. The collaboration also aims to fulfill international demand across Asia, Africa, Latin America, and select European markets.
[1] The partnership is actively engaging with leading hospital systems across India as part of its market rollout.
